Bartelink, H, Horiot, JC, Poortmans, P. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med. 2001;345(19):1378–1387.CrossRefGoogle ScholarPubMed

Bartelink, H, Horiot, JC, Poortmans, PM. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881–10882 trial. J Clin Oncol. 2007; 25(22):3259–3265.CrossRefGoogle ScholarPubMed

Creutzberg, CL, Putten, WL, Koper, PC. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000;355(9213):1404–1411.CrossRefGoogle Scholar

Hutchins, LF, Unger, JM, Crowley, JJ. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341(27):2061–2067.CrossRefGoogle ScholarPubMed

Wong, ND, Thakral, G, Franklin, SS. Preventing heart disease by controlling hypertension: impact of hypertensive subtype, stage, age, and sex. Am Heart J. 2003;145(5):888–895.CrossRefGoogle ScholarPubMed

Black, DM, Cummings, SR, Karpf, DB. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348(9041):1535–1541.CrossRefGoogle ScholarPubMed

Solin, LJ, Fourquet, A, Vicini, FA. Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer. 2005;103(6):1137–1146.CrossRefGoogle ScholarPubMed

Clarke, M, Collins, R, Darby, S. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087–2106.Google ScholarPubMed

Page, DL, Dupont, WD, Rogers, LW. Continued local recurrence of carcinoma 15–25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer. 1995;76(7):1197–1200.3.0.CO;2-0>CrossRefGoogle ScholarPubMed

Fonseca, R, Hartmann, LC, Petersen, IA. Ductal carcinoma in situ of the breast. Ann Intern Med. 1997;127(11):1013–1022.CrossRefGoogle ScholarPubMed

Fisher, B, Land, S, Mamounas, E. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol. 2001;28(4):400–418.CrossRefGoogle ScholarPubMed

Bijker, N, Meijnen, P, Peterse, JL. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853 – a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006;24(21):3381–3387.CrossRefGoogle ScholarPubMed

Emdin, SO, Granstrand, B, Ringberg, A. SweDCIS: radiotherapy after sector resection for ductal carcinoma in situ of the breast: results of a randomised trial in a population offered mammography screening. Acta Oncol. 2006;45(5):536–543.CrossRefGoogle Scholar

Houghton, J, George, WD, Cuzick, J. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 2003;362(9378):95–102.CrossRefGoogle ScholarPubMed

Viani, GA, Stefano, EJ, Afonso, SL. Breast-conserving surgery with or without radiotherapy in women with ductal carcinoma in situ: a meta-analysis of randomized trials. Radiat Oncol. 2007;2:28.CrossRefGoogle ScholarPubMed

Smith, BD, Haffty, BG, Buchholz, TA. Effectiveness of radiation therapy in older women with ductal carcinoma in situ. J Natl Cancer Inst. 2006;98(18):1302–1310.CrossRefGoogle ScholarPubMed

Charlson, ME, Pompei, P, Ales, KL. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40(5):373–383.CrossRefGoogle ScholarPubMed

Fisher, B, Anderson, S, Bryant, J. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233–1241.CrossRefGoogle ScholarPubMed

Veronesi, U, Cascinelli, N, Mariani, L. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227–1232.CrossRefGoogle ScholarPubMed

Hughes, KS, Schnaper, , Berry, D. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351(10):971–977.CrossRefGoogle ScholarPubMed

Hughes, KS, Schnaper, , Berry, D. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer: a report of further follow-up [abstract]. Proc San Antonio Breast Cancer Symp. 2006;A11.Google Scholar

Fyles, AW, McCready, DR, Manchul, . Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med. 2004;351(10):963–970.CrossRefGoogle ScholarPubMed

Carlson, RW, Anderson, BO, Burstein, HJ. Breast cancer. J Natl Compr Canc Netw. 2005;3(3):238–289.Google ScholarPubMed

Smith, BD, Gross, CP, Smith, GL. Effectiveness of radiation therapy for older women with early breast cancer. J Natl Cancer Inst. 2006;98(10):681–690.CrossRefGoogle ScholarPubMed

Overgaard, M, Hansen, PS, Overgaard, J. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997;337(14):949–955.CrossRefGoogle ScholarPubMed

Ragaz, J, Olivotto, IA, Spinelli, JJ. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005;97(2):116–126.CrossRefGoogle ScholarPubMed

Overgaard, M, Jensen, MB, Overgaard, J. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999;353(9165):1641–1648.CrossRefGoogle ScholarPubMed

Truong, PT, Lee, J, Kader, HA. Locoregional recurrence risks in elderly breast cancer patients treated with mastectomy without adjuvant radiotherapy. Eur J Cancer. 2005;41(9):1267– 1277.CrossRefGoogle ScholarPubMed

Smith, BD, Haffty, BG, Hurria, A. Postmastectomy radiation and survival in older women with breast cancer. J Clin Oncol. 2006;24(30):4901–4907.CrossRefGoogle ScholarPubMed

Whelan, T, MacKenzie, R, Julian, J. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst. 2002;94(15):1143–1150.CrossRefGoogle ScholarPubMed

Whelan, TJ, Pignol, JP, Julian, J. Long-term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node-negative breast cancer. Int J Radiat Oncol Biol Phys. 2008;72(suppl 1): S28.CrossRefGoogle Scholar

Bentzen, SM, Agrawal, RK, Aird, EG. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371(9618):1098–1107.Google ScholarPubMed

Bentzen, SM, Agrawal, RK, Aird, EG. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 2008;9(4):331–341.Google Scholar

Arthur, DW, Vicini, FA. Accelerated partial breast irradiation as a part of breast conservation therapy. J Clin Oncol. 2005;23(8):1726–1735.CrossRefGoogle ScholarPubMed

,NSABP Protocol B-39/RTOG Protocol 0413: a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. Radiation Therapy Oncology Group Web site. Available at: http://www.rtog.org/members/protocols/0413/0413.pdf.

Vlastos, G, Mirza, NQ, Meric, F. Breast conservation therapy as a treatment option for the elderly. The M. D. Anderson experience. Cancer. 2001;92(5):1092–1100.3.0.CO;2-P>CrossRefGoogle Scholar

Deutsch, M.Radiotherapy after lumpectomy for breast cancer in very old women. Am J Clin Oncol. 2002;25(1):48–49.CrossRefGoogle ScholarPubMed

D';Amico, AV, Whittington, R, Malkowicz, SB. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol. 2001;166(6):2185–2188.CrossRefGoogle Scholar

Bill-Axelson, A, Holmberg, L, Ruutu, M. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352(19):1977–1984.CrossRefGoogle ScholarPubMed

Mohler, J, Babaian, RJ, Bahnson, RR. Prostate cancer: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007;5(7):650–683.Google Scholar

McCloskey, SA, Kuettel, MR. Counterpoint: prostate cancer life expectancy can not be accurately predicted from currently available tools. J Natl Compr Canc Netw. 2007;5(7):709–713.CrossRefGoogle Scholar

Klotz, L.Active surveillance for prostate cancer: for whom?J Clin Oncol. 2005;23(32):8165–8169.CrossRefGoogle ScholarPubMed

Wong, YN, Mitra, N, Hudes, G. Survival associated with treatment vs observation of localized prostate cancer in elderly men. J Am Med Assoc. 2006;296(22):2683–2693.CrossRefGoogle ScholarPubMed

Albertsen, PC, Hanley, JA, Fine, J. 20-year outcomes following conservative management of clinically localized prostate cancer. J Am Med Assoc. 2005;293(17):2095–2101.CrossRefGoogle ScholarPubMed

Widmark, A, Klepp, O, Solberg, A. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009;373(9660):301–308.CrossRefGoogle ScholarPubMed

Bolla, M, Collette, L, Tienhoven, G. Ten year results of long term adjuvant androgen deprivation with goserelin in patients with locally advanced prostate cancer treated with radiotherapy: a phase III EORTC study [abstract]. Int J Radiat Oncol Biol Phys. 2008;72(suppl 1):A65, S30.CrossRefGoogle Scholar

Bolla, M, Collette, L, Blank, L. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360(9327):103–106.CrossRefGoogle ScholarPubMed

Bolla, M, Tienhoven, G, Reijke, TM. Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT – results of the randomized EORTC phase III trial 22961 [abstract]. J Clin Oncol. 2007;25(suppl 18):5238s.Google Scholar

Kuban, DA, Tucker, SL, Dong, L. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):67–74.CrossRefGoogle Scholar

Peeters, ST, Heemsbergen, WD, Koper, PC. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006;24(13):1990–1996.CrossRefGoogle ScholarPubMed

Zietman, AL, DeSilvio, ML, Slater, JD. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. J Am Med Assoc. 2005;294(10):1233–1239.CrossRefGoogle ScholarPubMed

Zelefsky, MJ, Levin, EJ, Hunt, M. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(4):1124–1129.CrossRefGoogle ScholarPubMed

Lawton, CA, DeSilvio, M, Roach, M. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys. 2007;69(3):646–655.CrossRefGoogle ScholarPubMed

Bach, PB, Cramer, LD, Warren, JL. Racial differences in the treatment of early-stage lung cancer. N Engl J Med. 1999;341(16):1198–1205.CrossRefGoogle ScholarPubMed

Bradley, J, Graham, MV, Winter, K. Toxicity and outcome results of RTOG 9311: a phase I–II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys. 2005;61(2):318–328.CrossRefGoogle ScholarPubMed

Fang, LC, Komaki, R, Allen, P. Comparison of outcomes for patients with medically inoperable stage I non-small-cell lung cancer treated with two-dimensional vs. three-dimensional radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66(1):108–116.CrossRefGoogle Scholar

Sibley, GS.Radiotherapy for patients with medically inoperable stage I nonsmall cell lung carcinoma: smaller volumes and higher doses – a review. Cancer. 1998;82(3):433–438.3.0.CO;2-Q>CrossRefGoogle Scholar

Lind, PA, Marks, LB, Hollis, D. Receiver operating characteristic curves to assess predictors of radiation-induced symptomatic lung injury. Int J Radiat Oncol Biol Phys. 2002;54(2):340–347.CrossRefGoogle ScholarPubMed

Starkschall, G, Forster, KM, Kitamura, K. Correlation of gross tumor volume excursion with potential benefits of respiratory gating. Int J Radiat Oncol Biol Phys. 2004;60(4):1291– 1297.CrossRefGoogle ScholarPubMed

Timmerman, RD, Park, C, Kavanagh, BD. The North American experience with stereotactic body radiation therapy in non-small cell lung cancer. J Thorac Oncol. 2007;2(7 suppl 3): S101–S112.CrossRefGoogle ScholarPubMed

Timmerman, R, McGarry, R, Yiannoutsos, C. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24(30):4833–4839.CrossRefGoogle Scholar

Chang, JY, Dong, L, Liu, H. Image-guided radiation therapy for non-small cell lung cancer. J Thorac Oncol. 2008;3(2):177–186.CrossRefGoogle ScholarPubMed

Chang, JY, Balter, PA, Dong, L. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;72(4):967–971.CrossRefGoogle ScholarPubMed

Dillman, RO, Herndon, J, Seagren, SL. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst. 1996;88(17):1210–1215.CrossRefGoogle Scholar

Sause, W, Kolesar, P, Taylor, SI. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest. 2000;117(2):358–364.CrossRefGoogle ScholarPubMed

Fournel, P, Robinet, G, Thomas, P. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d';Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95–01 Study. J Clin Oncol. 2005;23(25):5910–5917.CrossRefGoogle ScholarPubMed

Furuse, K, Fukuoka, M, Kawahara, M. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999;17(9):2692–2699.CrossRefGoogle ScholarPubMed

Huber, RM, Flentje, M, Schmidt, M. Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: study CTRT99/97 by the Bronchial Carcinoma Therapy Group. J Clin Oncol. 2006;24(27):4397–4404.CrossRefGoogle ScholarPubMed

Schild, SE, Stella, PJ, Geyer, SM. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol. 2003;21(17):3201–3206.CrossRefGoogle ScholarPubMed

Albain, KS, Rusch, VW, Crowley, JJ. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 1995;13(8):1880–1892.CrossRefGoogle Scholar

Meerbeeck, JP, Kramer, GW, Schil, PE. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst. 2007;99(6):442–450.CrossRefGoogle ScholarPubMed

Bradley, J. A review of radiation dose escalation trials for non-small cell lung cancer within the Radiation Therapy Oncology Group. Semin Oncol. 2005;32(2 suppl 3):S111–S113.CrossRefGoogle ScholarPubMed

Rosenzweig, KE, Fox, JL, Yorke, E. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma. Cancer. 2005;103(10):2118–2127.CrossRefGoogle ScholarPubMed

Ruysscher, D, Wanders, S, Haren, E. Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys. 2005;62(4):988–994.CrossRefGoogle ScholarPubMed

Rodrigues, G, Lock, M, D';Souza, D. Prediction of radiation pneumonitis by dose – volume histogram parameters in lung cancer – a systematic review. Radiother Oncol. 2004;71(2):127–138.CrossRefGoogle ScholarPubMed

Movsas, B, Scott, C, Langer, C. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. J Clin Oncol. 2005;23(10):2145–2154.CrossRefGoogle ScholarPubMed

Hensley, ML, Hagerty, KL, Kewalramani, T. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol. 2009;27(1):127–145.CrossRefGoogle Scholar

Mac Manus, MP, Hicks, RJ, Ball, DL. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer. 2001;92(4): 886–895.3.0.CO;2-V>CrossRefGoogle ScholarPubMed

Werner-Wasik, M, Scott, C, Cox, JD. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys. 2000;48(5):1475–1482.CrossRefGoogle ScholarPubMed

Turrisi 3rd, AT, Kim, K, Blum, R. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340(4):265–271.CrossRefGoogle Scholar

Yuen, AR, Zou, G, Turrisi, AT. Similar outcome of elderly patients in intergroup trial 0096: cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer. 2000;89(9):1953–1960.3.3.CO;2-Y>CrossRefGoogle ScholarPubMed

Auperin, A, Arriagada, R, Pignon, JP. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341(7):476–484.CrossRefGoogle ScholarPubMed

Arriagada, R, Chevalier, T, Borie, F. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst. 1995;87(3):183–190.CrossRefGoogle ScholarPubMed

Grosshans, DR, Meyers, CA, Allen, PK. Neurocognitive function in patients with small cell lung cancer: effect of prophylactic cranial irradiation. Cancer. 2008;112(3):589–595.CrossRefGoogle ScholarPubMed

Falk, SJ, Girling, DJ, White, RJ. Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial. Br Med J. 2002;325(7362):452–453.CrossRefGoogle ScholarPubMed

Erridge, SC, Gaze, MN, Price, A. Symptom control and quality of life in people with lung cancer: a randomised trial of two palliative radiotherapy fractionation schedules. Clin Oncol (R Coll Radiol). 2005;17(1):61–67.CrossRefGoogle ScholarPubMed

Kramer, GW, Wanders, SL, Noordijk, EM. Results of the Dutch national study of the palliative effect of irradiation using two different treatment schemes for non-small-cell lung cancer. J Clin Oncol. 2005;23(13):2962–2970.CrossRefGoogle ScholarPubMed

Sundstrom, S, Bremnes, R, Aasebo, U. Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial. J Clin Oncol. 2004;22(5):801–810.CrossRefGoogle ScholarPubMed

Gorlia, T, Bent, MJ, Hegi, ME. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981–22981/CE.3. Lancet Oncol. 2008;9(1):29–38.CrossRefGoogle ScholarPubMed

Curran Jr, WJ, Scott, CB, Horton, J. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993;85(9):704–710.CrossRefGoogle Scholar

Peschel, RE, Wilson, L, Haffty, B. The effect of advanced age on the efficacy of radiation therapy for early breast cancer, local prostate cancer and grade III–IV gliomas. Int J Radiat Oncol Biol Phys. 1993;26(3):539–544.CrossRefGoogle ScholarPubMed

Keime-Guibert, F, Chinot, O, Taillandier, L. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007;356(15):1527–1535.CrossRefGoogle ScholarPubMed

Roa, W, Brasher, PM, Bauman, G. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004;22(9):1583–1588.CrossRefGoogle ScholarPubMed

Bleehen, NM, Stenning, SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer. 1991;64(4):769–774.CrossRefGoogle ScholarPubMed

Stupp, R, Mason, WP, Bent, MJ. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996.CrossRefGoogle ScholarPubMed

,A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987–994.Google Scholar

Solal-Celigny, P, Roy, P, Colombat, P. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258–1265.CrossRefGoogle ScholarPubMed

Bonnet, C, Fillet, G, Mounier, N. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d';Etude des Lymphomes de l';Adulte. J Clin Oncol. 2007;25(7):787–792.CrossRefGoogle Scholar

Zelenetz, AD, Advani, RH, Byrd, JC. Non-Hodgkin's lymphomas. J Natl Compr Canc Netw. 2008;6(4):356–421.Google ScholarPubMed

Haas, RL, Poortmans, P, Jong, D. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol. 2003;21(13):2474– 2480.CrossRefGoogle ScholarPubMed

Haas, RL, Poortmans, P, Jong, D. Effective palliation by low dose local radiotherapy for recurrent and/or chemotherapy refractory non-follicular lymphoma patients. Eur J Cancer. 2005;41(12):1724–1730.CrossRefGoogle ScholarPubMed

Murthy, V, Thomas, K, Foo, K. Efficacy of palliative low-dose involved-field radiation therapy in advanced lymphoma: a phase ii study. Clin Lymphoma Myeloma. 2008;8(4): 241–245.CrossRefGoogle ScholarPubMed